

Summary

The Index was up 6.7% in 2025. The major contribution comes from Gold amounting to 5.9% of the overall performance, while US equities contributed positively, offset by a negative attribution of US bonds. (See Chart 3)

Chart 1: Index performance in 2025




Chart 2: Full period index annual performance

2008	2009	2010	2011	2012	2013	2014	2015	2016
1.2%	11.2%	16.2%	9.7%	4.8%	8.8%	9.2%	-4.4%	9.3%
2017	2018	2019	2020	2021	2022	2023	2024	2025
21.2%	0.9%	19.6%	16.5%	8.4%	-8.9%	8.2%	6.0%	6.7%

On average, the Index holds 41% weight in the S&P 500 futures, 45% in the U.S. 10-Year Treasury Notes futures and 12% in the gold futures, amounting to 98% allocation to target 6% volatility. Even though the Index has a 60%/30%/10% risk allocation, the low volatility of US bonds compared to US equities and Gold led to an allocation of US bonds in line with US equities.

ASSET CLASS CONTRIBUTION

US equities	US bonds	Gold
<p>US equities contributed 1.0% to the Index. The main underperformance came from the quick reaction to “Liberation Day” in April – the Index carried a rather low exposure to US equities in following S&P 500 positive performing months, when all volatility-control strategies suffered from such whipsaw markets.</p>	<p>US bonds contributed -0.2% to the Index. The gains were not captured in Q1 due to the Trend Signal that detected a strong rate hike which led to a deallocation to the US bond sleeve.</p>	<p>Gold contributed 5.9% to the Index. The year highlights why alternative assets such as Gold serve as an important diversifying factor in a Multi Asset portfolio compared to a traditional Equity and Bond portfolio. While the Index only has a 10% risk allocation into Gold, it contributed to most of the Index’s performance in 2025.</p>

Source: UBS, MerQube, and Bloomberg. Back-tested data range: June 18, 2008 - December 31, 2025. Live date is July 16, 2025. Live (historical) data range: July 16, 2025 - December 31, 2025. Index performance is net of all fees. Past performance is not necessarily indicative of future performance. This material contains data derived as a result of back-testing of data and is provided by UBS in good faith using our standard methodology for information of this kind.

ASSET CLASS CONTRIBUTION

Chart 3: 2021 - 2025 performance attribution by asset class

	US equities	US bonds	Gold	Total
Jan	0.1%	0.0%	0.7%	0.8%
Feb	-0.7%	0.0%	0.1%	-0.7%
Mar	-1.5%	0.2%	1.0%	-0.3%
Apr	-0.2%	1.0%	0.2%	0.9%
May	1.2%	-1.1%	0.0%	0.1%
Jun	2.3%	0.0%	-0.1%	2.2%
Jul	0.8%	-0.1%	-0.1%	0.6%
Aug	-0.1%	0.5%	1.0%	1.4%
Sep	0.6%	-0.1%	1.7%	2.1%
Oct	0.1%	-0.2%	0.6%	0.6%
Nov	-1.4%	0.3%	0.5%	-0.6%
Dec	-0.1%	-0.7%	0.2%	-0.6%
2025	1.0%	-0.2%	5.9%	6.7%
2024	5.3%	-1.1%	2.2%	6.0%
2023	8.4%	-0.2%	0.4%	8.2%
2022	-5.5%	-2.4%	-0.8%	-8.9%
2021	8.2%	0.7%	-0.1%	8.4%

US equities

The US equities allocation provides exposure to the S&P 500 futures through UBS US Equity Engle 10% Index.

- Even though the S&P 500 delivered a strong point-to-point performance in 2025, the year has been marked by low volatility from January to March, spiking to over 40% in April and May, and quickly stabilizing at a low level for the rest of the year. (See next page)
- The volatility-control mechanism within the US equities sleeve reacted quickly to “Liberation Day” in early April and managed to contain the loss at -1.4% in March and -0.2% in April. However, the US markets recovered very quickly subsequently. May, June and July were positive months for US equities, and a positive attribution was recorded; however, comparing to the S&P 500, the Index was carrying a low exposure to US equities and thus was not recovering as quickly. Note that in such whipsaw markets, all volatility-control indices suffered in the aftermath of “Liberation Day.”
- In addition, November recorded a negative attribution of -1.3% to the Index. The Index delivered good reactivity to downside markets up till 20 November. However, in the last week alone, the S&P 500 rallied significantly while the Engle mechanism forecasted a heightened volatility due to the drawdown suffered in the first half of November and allocated a low amount into US equities, leading to an overall negative attribution for the month.

Source: UBS, MerQube, and Bloomberg. Back-tested data range: December 31, 2020 - December 31, 2025. Live date is July 16, 2025. Live (historical) data range: July 16, 2025 - December 31, 2025. Index performance is net of all fees. Past performance is not necessarily indicative of future performance. This material contains data derived as a result of back-testing of data and is provided by UBS in good faith using our standard methodology for information of this kind.

ASSET CLASS CONTRIBUTION

US bonds

The US bonds allocation provides exposure to the U.S. 10-Year Treasury Notes futures through UBS US Dynamic Bond EMA Index.

- The Index was not allocated to bonds in the months of January, February, and June, while the Index had a relatively stable allocation for the rest of the months. In 2025, the US 10Y interest rates dropped from 4.2% at the start of the year to 3.6% towards the end of March. Subsequently interest rates have consolidated in a range between 3.6% and 4.0% for the rest of the year.
- The Index has missed out on most of US Treasury gains from January to March when it removed allocation into Bonds. This is due to the Trend signal which detected a strong rise in interest rates in December; however, interest rates subsequently fell in January and February and the Index missed out of bond price gains during those months. In May, a rally in rates from 3.6% to 4.0% caused the US bonds sleeve to suffer while it did not capture the turnaround in June as the Index deallocated due to the Trend signal. The Index captured the drop in rates in August and early September and recorded a positive gain in the month of August, while the rest of the year was marked by a consolidation in interest rates and bond prices.

Gold

The gold allocation provides exposure to the gold futures through UBS Gold Engle 10% Index.

- Gold had an extremely strong year considering heightened geopolitical tensions in 2025. On average, the Index holds 12% exposure in the gold futures because of applying a relatively low volatility target of 10% and a lower risk allocation of 10% into Gold. As a result, the Gold sleeve within the Index delivered a positive attribution of 5.9%.

Disclaimer

Attributions and Disclaimers with Respect to UBS

The UBS Multi Asset Engle SGD Index (the "Index") was developed by UBS AG. The Index applies a volatility control mechanism developed by UBS AG in collaboration with Engle Volatility Consulting LLC ("Engle Consulting"), the research principal of which is Robert F. Engle. UBS AG owns and is the current sponsor of the Index.

The rules of the Index may be amended by MerQube, Inc. (the "Calculation Agent") in consultation with UBS as index sponsor, which may, in turn, consult with Engle Consulting. An amendment to the rules may result from, without limitation, a change to the construction or calculation rules for the Index or from MerQube determining that a change to the rules is required or desirable in order to update them or to address an error, omission or ambiguity. No assurance can be given that any such amendment would not affect parties to this document. While volatility controls may result in less fluctuation in rates of return as compared to indices without volatility controls, they may also reduce the overall rate of return as compared to products not subject to volatility controls.

The end-of-day value of the Index is published subject to the provisions in the rules of the Index. Neither the Index Sponsor, the Calculation Agent or any of its affiliates is obliged to publish any information regarding the Index other than as stipulated in the rules of the Index.

This material has been issued by UBS AG and/or any of its affiliates ("UBS", "our", "we" and "us"). The securities, derivatives or other financial instruments described herein ("Instruments") may not be eligible for sale in all jurisdictions or to certain categories of investors. This material is for distribution only under such circumstances as may be permitted by applicable law, rules and/or regulations. All communications between you and us may be monitored.

Country-specific information For further important country-specific information, please see the following link: ubs.com/sales-and-trading-country-information.

Provenance and purpose This material has been prepared by UBS sales or trading personnel and it is not a product of our UBS Global Research Department and is not intended to recommend, suggest or inform an investment strategy. Opinions expressed may differ from the opinions expressed by our other divisions, including those of the UBS Global Research Department.

Recipient to exercise own judgment The information contained herein should not be regarded by recipients as a substitute for the exercise of their own judgment. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute the provision of investment advice. Prior to entering into a transaction, you should consult with your own legal, regulatory, tax, financial and accounting advisers to the extent you deem necessary to make your own investment, hedging and trading decisions.

Not an offer to transact This material has been prepared for informational purposes only and is not an offer to buy or sell, or a solicitation of an offer to buy or sell any Instrument or to participate in any particular trading strategy. This material is not an official confirmation of terms.

Contents of Material This material is prepared from information believed to be reliable, but we make no representations or warranties, express or implied, and owe no duties (including in negligence) as to the accuracy, completeness or reliability of the material, nor is it intended to be a complete statement or summary of the Instruments, markets or developments referred to. The material is subject to change without notice. We do not undertake any obligation to update this material. Any prices or quotations contained herein are indicative only and are not for valuation purposes. Past performance is not necessarily indicative of future results.

Conflicts of Interest This material may contain proprietary commentary produced in conjunction with our trading desks that trade as principal in the Instruments. This commentary may therefore not be independent from our proprietary interests or those of connected parties which may conflict with your interests. We may have accumulated, or may acquire, a long or short position in the subject Instrument, or related derivative, on the basis of this material prior to its dissemination. We may trade as principal or otherwise act, or have acted, as market-maker and/or as an execution venue in the Instruments. Instruments may be highly illiquid which may adversely impact the price, spread and speed of execution of orders in those Instruments. Furthermore, we may have, or have had, a relationship with or may provide, or have provided, investment banking, capital markets and/or other financial services to the companies associated with the Instruments.

We have policies and procedures in place which are designed to manage conflicts of interest. In order to control the flow of information contained in an area of UBS we may rely on information barriers. Additional information can be found at: ubs.com/ibterms.

Statement of Risk The Instruments are not suitable for all investors, and trading in these Instruments is considered risky and is appropriate only for sophisticated investors and in particular any target market identified herein. These Instruments may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates, foreign exchange rates and other market conditions. Some Instruments may be physically settled or cash settled.

No Liability To the fullest extent permitted by law, neither we nor any of our directors, employees or agents is liable for any loss (including indirect, special or consequential losses or damages, even if we have been advised of the possibility of such loss or damage) arising out of any person's use of, or reliance upon, the information contained herein.

Disclaimer

Securities Act Any Instruments that have not been registered under the United States Securities Act of 1933 may not be offered or sold in the United States except under an exception from the registration requirements of the Securities Act and applicable state securities laws.

No redistribution or reproduction We specifically prohibit the redistribution or reproduction of this material in whole or in part without our prior written permission and we accept no liability whatsoever for the actions of third parties in this respect.

Backtesting Disclaimer This material contains data derived as a result of back-testing of data and is provided by us in good faith using our standard methodology for information of this kind. That methodology relies on proprietary models, empirical data, assumptions and such other information that we believe to be accurate and reasonable. The current data that we selected for preparation of this material may be substantially different than if the data was selected from a different time period and this may have a substantial impact on the back-testing results. We make no representation as to the accuracy, completeness or appropriateness of such methodology and accept no liability for your use of the information. There is no assurance that other banks or brokers would derive the same results for the back-test period or that such results would have been achieved in practice. Prospective investors should also note that back-testing results may project unrealistic expectations on the performance of the relevant Instrument. Past performance is not necessarily indicative of future results. The back-testing results do not account for the risks involved in investing in the relevant Instrument, including but not limited to the credit risk of the issuer of the Instrument. These risks may lead to the loss of any investors' investment in the relevant Instrument.

Scenario Analysis The scenario analyses shown in this material are based on model-based valuation methodologies and the results provided by them may vary significantly depending (i) on the data used as inputs; and (ii) on the assumptions and other parameters embedded in the model, which are not the only ones that might reasonably have been selected. They are based in part on information and market data which may be subject to change. We are not under any obligation to update the analyses. The scenario analyses are illustrative only and present hypothetical performance analyses of the Index based on certain assumptions with respect to specific factors that may prove to be incorrect. They are not intended to predict actual results for the Index and actual results may differ substantially from those provided or projected. We make no representation or warranty, express or implied, as to the accuracy or completeness or fitness for use for any particular purpose of the analysis or calculation methodology used. You should review and understand the assumptions and evaluate whether they are appropriate for your purposes.

Engle Consulting Disclaimer Engle Consulting is not an investment adviser, does not guarantee the accuracy and completeness of the Index or any product referencing the Index or any data or methodology either included therein or

upon which it is based. Neither the Index nor any product referencing the Index is sponsored, endorsed, sold or promoted by Engle Consulting or Robert F. Engle. ENGLE CONSULTING AND ROBERT F. ENGLE DO NOT MAKE ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, TO ANY FINANCIAL INSTITUTION, INVESTOR OF OR COUNTERPARTIES TO THE INDEX OR ANY PRODUCT REFERENCING THE INDEX OR TO ANY MEMBER OF THE PUBLIC REGARDING ANY PRODUCT REFERENCING THE INDEX OR THE ADVISABILITY OF INVESTING IN SECURITIES GENERALLY OR IN THE INDEX OR ANY PRODUCT REFERENCING THE INDEX PARTICULARLY. NEITHER ENGLE CONSULTING NOR ROBERT F. ENGLE OR ANY OF THEIR RESPECTIVE PARTNERS, EMPLOYEES, SUBCONTRACTORS, AGENTS, SUPPLIERS, VENDORS, HEIRS SUCCESSORS AND ASSIGNS (COLLECTIVELY, THE "PROTECTED PARTIES") SHALL HAVE ANY LIABILITY FOR ANY ERRORS, OMISSIONS OR INTERRUPTIONS IN THE INDEX OR ANY PRODUCT REFERENCING THE INDEX AND MAKE NO WARRANTIES EXPRESSED OR IMPLIED, AS TO THE PERFORMANCE OR RESULTS EXPERIENCED BY ANY PARTY FROM THE USE OF ANY INFORMATION INCLUDED THEREIN OR UPON WHICH IT IS BASED, AND EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT THERETO, AND SHALL NOT BE LIABLE FOR ANY CLAIMS OR LOSSES OF ANY NATURE IN CONNECTION WITH THE INDEX OR ANY PRODUCT REFERENCING THE INDEX OR THE USE OF SUCH INFORMATION, INCLUDING BUT NOT LIMITED TO, LOST PROFITS OR PUNITIVE, INDIRECT OR CONSEQUENTIAL DAMAGES EVEN IF ENGLE CONSULTING, ROBERT F. ENGLE OR ANY PROTECTED PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

MerQube, Inc. MerQube, Inc. calculates the UBS Multi Asset Engle SGD Index for UBS AG. MerQube, Inc. does not guarantee the accuracy, timeliness, or completeness of the calculations or any data or information relating to the Index. MerQube, Inc. makes no warranty, express or implied, as to the Index, or any values or data related thereto or results to be obtained therefrom, and expressly disclaims all warranties of merchantability and fitness for a particular purpose with respect thereto. To the maximum extent permitted by law, MerQube, Inc., its affiliates, and all their respective employees, subcontractors, partners, agents, suppliers, and vendors (collectively, the "protected parties") shall have no liability, contingent or otherwise, for any injury or damages, whether caused by the negligence of a protected party or otherwise, arising in connection with the calculation of the Index or any data or values included therein or in connection therewith and shall not be liable for any losses (including lost profits), punitive, incidental, or consequential damages.

Additional UBS disclosure in respect of MerQube

Prospective investors in any product linked to any index in respect of which MerQube acts as index administrator and/or calculation agent should be aware that as at the time of issuance, UBS AG and/or its affiliates ("UBS") has made an investment in shares in MerQube and accordingly holds up to 5% of MerQube's share capital. In certain situations, this may create a conflict of interest between UBS and any investors in the product.